Stay updated on Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check20 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.7%
- Check27 days agoNo Change Detected
- Check48 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check62 days agoChange DetectedThe page has removed significant details about a Phase 1b study evaluating lenvatinib and pembrolizumab for hepatocellular carcinoma, including the study's design, objectives, and inclusion/exclusion criteria, while adding a new identifier and revision number.SummaryDifference7%
- Check70 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check77 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial page.